These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 31088111)

  • 21. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
    Wykoff CC; Brown DM; Maldonado ME; Croft DE
    Br J Ophthalmol; 2014 Jul; 98(7):951-5. PubMed ID: 24518078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial.
    DeCroos FC; Reed D; Adam MK; Salz D; Gupta OP; Ho AC; Regillo CD
    Am J Ophthalmol; 2017 Aug; 180():142-150. PubMed ID: 28624325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.
    Inoue M; Yamane S; Sato S; Sakamaki K; Arakawa A; Kadonosono K
    Am J Ophthalmol; 2016 Sep; 169():95-103. PubMed ID: 27320059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
    Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
    Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies.
    Dugel PU; Jhaveri CD; Chakravarthy U; Wykoff CC; Singh RP; Hamilton R; Weissgerber G; Mulyukov Z; Holz FG
    Retina; 2022 Mar; 42(3):511-518. PubMed ID: 34923515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Loading Doses of Ziv-Aflibercept and Aflibercept in Neovascular Age-Related Macular Degeneration.
    Ayachit A; Singh SR; Subramanyam A; Tiwari S; Heranjal A; Chattannavar G; Pandey P; Salti H; Mansour MA; Mansour A; Chhablani J
    Asia Pac J Ophthalmol (Phila); 2020; 9(2):144-148. PubMed ID: 32175924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
    de Massougnes S; Dirani A; Mantel I
    Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ASSESSMENT OF EARLY CHANGES IN SPECTRAL DOMAIN-OPTICAL COHERENCE TOMOGRAPHY AFTER INITIATION OF TREATMENT WITH INTRAVITREAL AFLIBERCEPT (EYLEA) OVER A 12-WEEK PERIOD FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Multicenter French Study (START).
    Korobelnik JF; Souied EH; Oubraham H; Razavi S; Mauget-Faÿsse M; Savel H; Chene G; Wolf S
    Retina; 2021 Mar; 41(3):588-594. PubMed ID: 33600134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.
    Muftuoglu IK; Arcinue CA; Tsai FF; Alam M; Gaber R; Camacho N; You Q; Freeman WR
    Am J Ophthalmol; 2016 Jul; 167():1-9. PubMed ID: 27049000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results.
    Aghdam KA; Pielen A; Framme C; Junker B
    Eur J Ophthalmol; 2016 Aug; 26(5):473-8. PubMed ID: 26868007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching from ranibizumab to aflibercept in choroidal neovascularization secondary to angioid streaks.
    Sekfali R; Mimoun G; Cohen SY; Querques G; Bandello F; Sacconi R; Souied EH; Capuano V
    Eur J Ophthalmol; 2020 May; 30(3):550-556. PubMed ID: 30880436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.
    Jaffe GJ; Kaiser PK; Thompson D; Gibson A; Saroj N; Vitti R; Berliner AJ; Heier JS
    Ophthalmology; 2016 Sep; 123(9):1856-64. PubMed ID: 27369111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
    Pinheiro-Costa J; Costa JM; Beato JN; Freitas-da-Costa P; Brandão E; Falcão MS; Falcão-Reis F; Carneiro ÂM
    Ophthalmologica; 2015; 233(3-4):155-61. PubMed ID: 25896317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Identification of Choroidal Neovascularization Activity by Location and Quantification of Abnormal Fluid Under Anti-Vascular Endothelial Growth Factor Therapy.
    Farinha C; Santos T; Santos AR; Lopes M; Alves D; Silva R; Cunha-Vaz J
    Retina; 2020 May; 40(5):881-890. PubMed ID: 30689620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW.
    Weber M; Dominguez M; Coscas F; Faure C; Baillif S; Kodjikian L; Cohen SY
    BMC Ophthalmol; 2020 May; 20(1):206. PubMed ID: 32450838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SAVING SIGHT IN NEOVASCULAR AMD.
    Retina; 2020 Jul; 40 Suppl 2():S1-S12. PubMed ID: 32558673
    [No Abstract]   [Full Text] [Related]  

  • 38. The VEGF Treatment of AMD Switch Study (The vTAS Study).
    Curry B; Bylsma G; Hewitt AW; Verma N
    Asia Pac J Ophthalmol (Phila); 2017; 6(6):481-487. PubMed ID: 29204996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
    Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
    Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept.
    Chatziralli I; Nicholson L; Vrizidou E; Koutsiouki C; Menon D; Sergentanis TN; Citu MC; Hamilton R; Patel PJ; Hykin P; Sivaprasad S
    Ophthalmology; 2016 Aug; 123(8):1762-1770. PubMed ID: 27289179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.